Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

The conversation is about finding a gentle topical treatment for a sensitive scalp with seborrheic dermatitis. Suggestions include using Trichosol/Trichofoam-based topical finasteride/minoxidil, which is considered gentle on the scalp.

The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.

Exploring a potential hair loss treatment using the enzyme AKR1C2 to locally reduce DHT levels. Challenges include enzyme delivery through the skin and high production costs, with gene therapy or stem cells suggested as future alternatives.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

DHT negatively affects scalp hair while promoting body hair growth, causing frustration due to the lack of permanent solutions for baldness. Users discuss treatments like finasteride and potential future solutions like CRISPR technology.

A user is seeking help to purchase and ship Alpecin DMG to the United States due to issues with eBay sellers. They prefer Alpecin DMG over minoxidil because of concerns about minoxidil's effects on insulin production, as they have diabetes.

Twist-1 is being explored as a promising early-stage hair loss treatment, while Scube-3's effect on Twist-1 in breast cancer cells raises concerns about its use for hair loss. The conversation discusses the potential differences in protein effects across various cell types.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.

Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.

The conversation discusses the complexity of reversing hair loss and the need for a treatment that specifically targets DHT levels without affecting other bodily functions. It mentions finasteride as a current treatment but highlights the desire for a solution that works solely on the scalp.

Mixing clascoterone with minoxidil involves using 99% ethanol and propylene glycol. Users discuss the effectiveness and potential side effects of this DIY solution.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Vitamin D deficiency can hinder hair recovery, and addressing it may help with hair loss. Hair loss may result from various issues like excess DHT, vitamin deficiency, or scalp inflammation.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

An 18-year-old experiencing hair loss and seborrheic dermatitis has tried finasteride, dutasteride, and various shampoos without success. They are considering anti-androgens like RU58841 and KX-826 for oil control and dandruff reduction.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

The conversation discusses a user's worsening scalp condition, possibly seborrheic dermatitis, despite using keto shampoo. Suggestions include using MCT C8 oil, adjusting diet by reducing carbs and sugars, and consulting a dermatologist.

Clascoterone stopped shedding for one user, but no visual regrowth was noted after 3 months. The user experienced side effects with finasteride, dutasteride, and RU58841, but not with oral minoxidil and clascoterone.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.